[ET Net News Agency, 8 April 2020] Guotai Junan International lowered its target price
for CSPC Pharmaceutical Group (01093) to HK$22.5 from HK$24.9 and maintained its "buy"
rating.
The research house said CSPC's 2019 results were broadly in line with Guotai Junan's
expectation. Due to the outbreak of COVID-19, medical demand was depressed, and thus the
number of prescriptions dropped in China. As the outbreak was effectively controlled in
China, Guotai Junan expects that CSPC's marketing and R&D will return to normal starting
from 2Q.
Looking ahead to 2020, Guotai Junan believes that the bottom-line growth of CSPC could
still approach nearly 20%, with consideration to the robust growth momentum of its
existing products and a rich and productive pipeline serving as new engines. (KL)